<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03256721</url>
  </required_header>
  <id_info>
    <org_study_id>SECGOLC003</org_study_id>
    <nct_id>NCT03256721</nct_id>
  </id_info>
  <brief_title>Compare Apatinib Plus Chemotherapy Drug Versus Chemotherapy Drug as Second-line Treatment in NSCLC</brief_title>
  <official_title>A Randomized, Parallel Control, Exploratory Trial to Compare Apatinib Plus Chemotherapy Drug Versus Chemotherapy Drug as Second-line Treatment in Subjects With Advanced or Metastatic of the Non-small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fuzhou General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fuzhou General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Apatinib, a novel targeted inhibitor of VEGF receptor 2 (VEGFR2), shows significant antitumor&#xD;
      activity in the patients with GC. The purpose of this study is to determine whether apatinib&#xD;
      plus chemotherapy drug can improve progression free survival compared with chemotherapy drug&#xD;
      in patients with metastatic the non-small cell lung cancer who failed one lines of&#xD;
      chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lung cancer is the leading cause of cancer death in world wild, especially non-small cell&#xD;
      lung cancer (NSCLC). Detection and early intervention are difficult because pathogenesis of&#xD;
      NSCLC is not yet entirely clear.Most of them are advanced or metastatic patients, so approach&#xD;
      3/4 NSCLC undergo chemotherapy. Fewer treatment options exist on NSCLC whom is wild type of&#xD;
      EGFR. The patient did not benefit from the existing treatment regimen after first-line&#xD;
      treatment. There is currently no effective drug to treat this group of patients.&#xD;
&#xD;
      Apatinib, a novel targeted inhibitor of VEGF receptor 2 (VEGFR2), shows significant antitumor&#xD;
      activity in the patients with GC. The purpose of this study is to determine whether apatinib&#xD;
      plus chemotherapy drug can improve progression free survival compared with chemotherapy drug&#xD;
      in patients with metastatic the non-small cell lung cancer who failed one lines of&#xD;
      chemotherapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to the enrollment was slow and exceeded the expected enrollment time&#xD;
  </why_stopped>
  <start_date type="Actual">August 16, 2017</start_date>
  <completion_date type="Actual">August 16, 2019</completion_date>
  <primary_completion_date type="Actual">March 27, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Group A: Apatinib 500mg QD PO d1-21 + Docetaxel (75mg/m2 IV d1)/Pemetrexed (500 mg/m2 IV d1), q21d&#xD;
Group B: Docetaxel (75mg/m2 IV d1)/Pemetrexed (500 mg/m2 IV d1), q21d</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months</time_frame>
    <description>To compare progression-free survival (PFS) in subjects treated with apatinib plus chemotherapy drug versus chemotherapy drug as a second-line treatment in whom with advanced or metastatic non-small cell lung cancer (NSCLC)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Nonsmall Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Apatinib+docetaxel/pemetrexed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apatinib 500mg QD PO d1-21+docetaxel(75mg/m2 IV d1)/pemetrexed(500 mg/m2 IV d1),q21d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>docetaxel/pemetrexed</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>docetaxel(75mg/m2 IV d1)/pemetrexed(500 mg/m2 IV d1),q21d</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib/docetaxel/pemetrexed</intervention_name>
    <description>Participants are randomly assigned to treatment group or control group</description>
    <arm_group_label>Apatinib+docetaxel/pemetrexed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel/pemetrexed</intervention_name>
    <description>Participants are randomly assigned to treatment group or control group</description>
    <arm_group_label>docetaxel/pemetrexed</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age：18~75 years;&#xD;
&#xD;
          2. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          3. Subjects with histologically or cytologically confirmed locally advanced or advanced&#xD;
             NSCLC who have previously received no more than one lines treatment before&#xD;
             participating；&#xD;
&#xD;
          4. Subjects with at least one measurable lesion as defined by RECIST (version 1.1),which&#xD;
             is confirmed by computed tomography (CT) scan or MRI .&#xD;
&#xD;
          5. EGFRˉ,and ALK mutation in the negative or unknown；&#xD;
&#xD;
          6. Subjects without brain metastases or asymptomatic brain metastases, and not needing&#xD;
             for dehydrating agents or corticosteroids to control intracranial symptoms;&#xD;
&#xD;
          7. Survival expectation≥ 3 months;&#xD;
&#xD;
          8. The main organ function is normal;&#xD;
&#xD;
          9. Females of childbearing potential must be a pregnancy test in 7 days before&#xD;
             participating ( including serum or urine), and the results were negative.&#xD;
&#xD;
         10. Subjects provided written informed consent before participating,Willing and able to&#xD;
             comply with all aspects of the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Small Cell Lung Cancer;&#xD;
&#xD;
          2. Subjects with symptomatic brain metastases;&#xD;
&#xD;
          3. Survival expectation &lt; 3 months;&#xD;
&#xD;
          4. Blood transfusion is required in the first dose of drug treatment within 14 days ;&#xD;
&#xD;
          5. The interval of subjects had received chemotherapy, biotherapy, radiotherapy or other&#xD;
             anticancer therapies in the first dose of drug treatment within 21 days(excluding&#xD;
             palliative radiotherapy);&#xD;
&#xD;
          6. The risk of active bleeding;&#xD;
&#xD;
          7. Subjects with uncontrolled blood pressure with medication (140/90 mmHg)&#xD;
&#xD;
          8. Laboratory values and organ functions ： （1）Hematologic insufficiency:&#xD;
&#xD;
               1. Hemoglobin (Hb)&lt;8.5 g/dL，&#xD;
&#xD;
               2. Absolute neutrophil count (ANC)≤1.5×109/L，&#xD;
&#xD;
               3. Platelet count (PLT)&lt; 100×109/L； （2）Insufficient liver function:&#xD;
&#xD;
               1. Bilirubin &gt; 1.5×the upper limit of normal (ULN)&#xD;
&#xD;
               2. Alanine aminotransferase (ALT), or Aspartate aminotransferase (AST) &gt;3.0×(ULN),&#xD;
                  When liver metastases,Bilirubin &gt; 1.5×ULN, ALT or AST &gt;5.0×(ULN.&#xD;
&#xD;
               3. serum creatinine ≤1.0×（ULN）, or creatinine clearance &gt; 50 mL/min( calculated per&#xD;
                  the Cockcroft and Gault formula) (3) Subjects with positive for HBV&#xD;
                  surfaceantigen ( HBsAg)or anti-hcv (4)Subjects with Interstitial lung disease&#xD;
                  (5)Insufficient renal function: serum creatinine≥ 1.5×（ULN）, or creatinine&#xD;
                  clearance &lt;60 mL/min&#xD;
&#xD;
          9. impairment of heart function: (1)Left ventricular ejection fraction (LVEF) &lt;45% (LVEF&#xD;
             evaluation is not required for subjects have no history of congestive heart failure),&#xD;
             (2)Unstable angina, (3)Severe arrhythmia, (4)NYHA III or IVgrade of congestive heart&#xD;
             failure, (5) Subjects with miocardial infarction within the last 12 months before&#xD;
             entering the trial, (6)Pericardial effusion,&#xD;
&#xD;
         10. Subjects with liver fibrosis or hepatic cirrhosis&#xD;
&#xD;
         11. (1)Subjects with other active malignancy (except for definitively treated non melanoma&#xD;
             skin cancer,carcinoma in-situ of the cervix,or other cancers that are treated with&#xD;
             curative treatment and have no signs of recurrence for at least 5 years ) ,&#xD;
             (2)Subjects with dysphagia,malabsorption,chronic gastrointestinal diseases,or other&#xD;
             medical history may hinder compliance and / or experimental drug absorption,&#xD;
&#xD;
         12. Subjects with major surgery in the first dose of drug treatment within 28 days,&#xD;
&#xD;
         13. Subjects with positive foknown human immunodeficiency virus。&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fuzhou general hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>365000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 16, 2017</study_first_submitted>
  <study_first_submitted_qc>August 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2017</study_first_posted>
  <last_update_submitted>February 3, 2021</last_update_submitted>
  <last_update_submitted_qc>February 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>apatinib docetaxel pemetrexed</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

